Page 4 - Aduhelm News Today

The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.

Lecanemab appeared to slow down cognitive decline in people with early Alzheimer's, though some experts question its real-world benefits.

Two House of Representatives committees – Oversight and Reform, and Energy and Commerce – have published a report exposing the Food and Drug Administration (FDA) for "collaborat[ing]" [...]

The prominent economist Milton Friedman said that in order to understand the motivation of a person or organization, you must look for the self-interest. So where do regulators' interests lie? Not always in the public interest, alas, but in increased responsibilities, budgets, bureaucratic empires, and avoiding bad decisions.

The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”

THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administrations approval process for the controversial Alzheimers drug Aduhelm was "rife with irregularities," despite lingering doubts about the

THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approval process for the controversial Alzheimer drug Aduhelm was "rife with irregularities," despite lingering doubts about the

The U.S. Food and Drug Administration's (FDA) approval process of the controversial and costly new Alzheimer’s drug Aduhelm was "rife with irregularities" ...

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

The investigation found that Biogen knew the drug's hefty price tag would make the medication inaccessible to many patients.